Photo: Scroll
4 More Vaccines Under Development, Says SII Executive Director
Executive Director of Serum Institute of India (SII), Suresh Jadhav, has informed that the company is currently working on four more covid-19 vaccines apart from Covishield. Suresh said, "Three others are in different stages of clinical studies while one is in the pre-clinical stage of the trial". Reportedly, SII has collaborated with US firms like Codagenix and Novavax inc aiming to produce 200 crore doses of vaccine.
Tags: SII, Suresh Jadhav, COVISHIELD, Coronavirus Vaccine
Courtesy: Business Insider
Photo: Global Times
India Kick-Starts Dry Run For COVID-19 Vaccine In 116 Districts
Gearing to launch mass vaccination drive, the Centre on January 2 began a dry run of COVID-19 vaccination programme in 116 districts across all states/UTs. The first national dry run will reportedly cover 16% of the 734 districts of India. Union Health Minister Harsh Vardhan informed that he would personally visit some centres in Delhi. Moreover, eying on the India's Drug Controller’s approval, the Serum Institute of India has already… read-more
Tags: India, Covid-19 Vaccine, SII, Dr Harsh Vardhan
Courtesy: The Tribune
Photo: Punekar News
Covishield To Cost Rs 440 At Govt Stores: SII CEO Adar Poonwalla
Serum Institute of India (SII) CEO Adar Poonawalla on December 31 stated that the Covishield vaccine would be sold at Rs 440 ($6) in the government stores. However, the prices at private markets have been estimated at around Rs 700-800. The SII got approval for Emergency Use Authorization (EUA) of Oxford-AstraZeneca vaccine in the UK on December 30. Reportedly, 40 million doses of Covishield vaccine have already been manufactured.
Tags: SII, COVISHIELD, Oxford-AstraZeneca, Adar Poonawalla
Courtesy: India.com
